Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: A meta-analysis

Table 1 The main characteristics of the 8 selected studies

First Author	Year	Type of study	n	Chemotherapy regimen
				Ctx only	Ctx plus iri	Ctx plus folfiri	Ctx plus folfox	Pan	Ctx plus oxa	Ctx plus oxa and cap
Sartore-Bianchi et al[3]	2009	Cohort study	110	14	74	0	0	22	0	0
Negri et al[5]	2009	Retrospective study	50	0	36	0	0	0	14	0
Laurent-Puig et al[9]	2009	Retrospective study	173	3	141	28	0	0	0	0
Loupakis et al[10]	2009	Retrospective cohort study	102	2	100	0	0	0	0	0
Perrone et al[21]	2009	Cohort study	32	0	32	0	0	0	0	0
Frattini et al[20]	2007	Cohort study	27	0	23	0	0	0	0	4
Razis et al[22]	2008	Retrospective study	72	1	13	27	18	-	-	-
Sartore-Bianchi et al[23]	2009	Cohort study	132	15	94	0	0	23	0	0

CTX: Cetuximab; Pan: Panitumumab; oxa: Oxaliplaten; cap: Capecitabine.